Literature DB >> 10671875

The effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyper-reflexia.

P Dasgupta1, V A Chandiramani, A Beckett, F Scaravilli, C J Fowler.   

Abstract

OBJECTIVE: To determine the effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyper-reflexia, in whom a single dose of intravesical capsaicin (1-2 mmol/L) increases the bladder capacity for 3-6 months. PATIENTS AND METHODS: Thirteen patients with detrusor hyper-reflexia underwent cystometry and had flexible cystoscopic biopsies taken before and 6 weeks after receiving instillations of intravesical capsaicin (1 mmol/L). Similar biopsies were also obtained from a control group of 12 neurologically normal patients with microscopic haematuria and normal bladders. Frozen sections were stained using antibodies to S100 and PGP 9.5. Using computerized analysis, the mean nerve density scores were expressed as nerves/mm2 for S100-positive structures and 'red%' and 'red in frame' for PGP 9.5.
RESULTS: The mean (SEM) functional bladder capacity increased from 193.2 (28.17) mL before to 396.3 (41.96) mL at 6 weeks after treatment with capsaicin, in nine of the 13 patients. The mean nerve density of S100-positive structures in the control group was 83 (3.18) nerves/mm2. In hyper-reflexic patients who responded to capsaicin by improved bladder capacity, the mean nerve density of S100-positive structures was reduced from 100 (12.2) before to 66 (9.4) nerves/mm2 6 weeks after treatment. In those who did not respond to capsaicin there was no significant difference in these scores. Similarly the 'red%' and 'red in frame' reduced from 3.41 (1.06) to 1.15 (0.32) and 824.7 (246.3) to 297.9 (83.5) units, respectively, before and 6 weeks after capsaicin treatment. The difference in those not responding was not significant.
CONCLUSIONS: Intravesical capsaicin causes a reduction in suburothelial nerve densities in the bladder of patients with detrusor hyper-reflexia. This may explain its prolonged beneficial effect in these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10671875     DOI: 10.1046/j.1464-410x.2000.00427.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

Review 1.  Recent advances in intravesical drug/gene delivery.

Authors:  Pradeep Tyagi; Pao-Chu Wu; Michael Chancellor; Naoki Yoshimura; Leaf Huang
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

Review 2.  Sensing the air around us: the voltage-gated-like ion channel family.

Authors:  Dennis Kim; James N Baraniuk
Journal:  Curr Allergy Asthma Rep       Date:  2007-05       Impact factor: 4.806

Review 3.  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

Authors:  António Avelino; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-24       Impact factor: 3.000

4.  Pathophysiology of overactive bladder and urge urinary incontinence.

Authors:  William D Steers
Journal:  Rev Urol       Date:  2002

Review 5.  Vanilloid-induced conduction analgesia: selective, dose-dependent, long-lasting, with a low level of potential neurotoxicity.

Authors:  Igor Kissin
Journal:  Anesth Analg       Date:  2008-07       Impact factor: 5.108

6.  The effects of intraarticular resiniferatoxin in experimental knee-joint arthritis.

Authors:  Eugene Y Kissin; Cristina F Freitas; Igor Kissin
Journal:  Anesth Analg       Date:  2005-11       Impact factor: 6.627

7.  Intraluminal Administration of Resiniferatoxin Protects against Clostridium difficile Toxin A-Induced Colitis.

Authors:  Steven R Vigna
Journal:  Gastroenterol Res Pract       Date:  2017-04-17       Impact factor: 2.260

8.  TRPV1: a target for next generation analgesics.

Authors:  Louis S Premkumar; Parul Sikand
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.